CTLA4 and neoplasm: CTLA-4/B7 function in different phases in comparison to the PD-1/PD-L1 axis, and thus synergistic inhibition of both signaling pathways offers a potential solution to reduce tumor resistance during ICI monotherapy (113, 114).